NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,https://clinicaltrials.gov/study/NCT01023308,PANORAMA-1,COMPLETED,"Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) patients treated by oral panobinostat and i.v bortezomib ± dexamethasone showed very encouraging results for efficacy and manageable toxicity profile.

Given the medical need for improved treatment strategies for patients with previously treated and relapsed MM, the purpose of this prospective, multinational, randomized, double-blind, placebo-controlled, parallel group Phase III study is to compare the results in progression-free survival of 2 combination therapies, panobinostat with bortezomib and dexamethasone or placebo with bortezomib and dexamethasone, in patients with previously treated MM whose disease has recurred or progressed.",YES,Multiple Myeloma,DRUG: Panobinostat|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Placebo,"Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., 45 months|Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., 45 months","Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone, Number of OS events, 45 months|Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone, survival time in months, 45 months|Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., Best overall response based on mEBMT criteria per investigator assessment, 45 months|Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., 45 months|Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., 45 months|Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone., 45 months|European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC) QLQ-MY20-Change From Baseline by Treatment Group, Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)"", All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms., 12, 24 and 48 weeks|European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC ) QLQ-C30 - Summary Statistics by Treatment Group, The EORTC QLQ-C30 measures functional dimensions (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), six single-item symptom scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. Disease Symptom is the sum of 30 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)"", All subscales of EORTC QLQ-C30 have the same score range of 0 -100. For global health status and other functional scales,an increase from baseline indicates improvement of QoL. Whereas for symptoms scales, fatigue, dyspnea, insomnia, appetite loss, constipation and diarrhea, decrease in scores from baseline indicate improvement in symptoms., 12, 24 and 48 weeks|Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System : FACT/GOG-NTX-Change From Baseline by Treatment Group, Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, scale 0 -28, , NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement., 12, 24 and 48 weeks",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,767,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CLBH589D2308|2009-015507-52,2009-12-21,2015-07-30,2015-07-30,2009-12-02,2015-10-23,2020-03-17,"Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Anaheim, California, 92801, United States|Novartis Investigative Site, Concord, California, 94520, United States|Novartis Investigative Site, Los Angeles, California, 90027, United States|Novartis Investigative Site, San Diego, California, 92120, United States|Novartis Investigative Site, Stanford, California, 94304, United States|Novartis Investigative Site, Boca Raton, Florida, 33486, United States|Novartis Investigative Site, Lake Worth, Florida, 33467, United States|Novartis Investigative Site, Miami Shores, Florida, 33138, United States|Novartis Investigative Site, Athens, Georgia, 30607, United States|Novartis Investigative Site, Atlanta, Georgia, 30322, United States|Novartis Investigative Site, Marietta, Georgia, 30060, United States|Novartis Investigative Site, Marywood, Illinois, 60153, United States|Novartis Investigative Site, Quincy, Illinois, 62301, United States|Novartis Investigative Site, New Orleans, Louisiana, 70115, United States|Novartis Investigative Site, Baltimore, Maryland, 21229, United States|Novartis Investigative Site, Rockville, Maryland, 20850, United States|Novartis Investigative Site, Boston, Massachusetts, 02215, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Edina, Minnesota, 55435, United States|Novartis Investigative Site, Minneapolis, Minnesota, 55404, United States|Novartis Investigative Site, Columbia, Missouri, 65201, United States|Novartis Investigative Site, East Orange, New Jersey, 07018-1095, United States|Novartis Investigative Site, Mount Kisco, New York, 10549, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Bismarck, North Dakota, 58501, United States|Novartis Investigative Site, Dayton, Ohio, 45429, United States|Novartis Investigative Site, Middletown, Ohio, 45042, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, 15224, United States|Novartis Investigative Site, East Providence, Rhode Island, 02915, United States|Novartis Investigative Site, Nashville, Tennessee, 37203, United States|Novartis Investigative Site, Nashville, Tennessee, 37232, United States|Novartis Investigative Site, Amarillo, Texas, 79106, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, Kennewick, Washington, 99336, United States|Novartis Investigative Site, Seattle, Washington, 98104, United States|Novartis Investigative Site, Walla Walla, Washington, 33962, United States|Novartis Investigative Site, Morgantown, West Virginia, 26506, United States|Novartis Investigative Site, La Plata, Buenos Aires, B1900AWT, Argentina|Novartis Investigative Site, Buenos Aires, C1114AAN, Argentina|Novartis Investigative Site, Cordoba, X5000JHQ, Argentina|Novartis Investigative Site, St Leonards, New South Wales, 2065, Australia|Novartis Investigative Site, Herston, Queensland, 4029, Australia|Novartis Investigative Site, Woolloongabba, Queensland, 4102, Australia|Novartis Investigative Site, Franston, Victoria, 3199, Australia|Novartis Investigative Site, Nedlands, Western Australia, 6009, Australia|Novartis Investigative Site, Perth, Western Australia, 6000, Australia|Novartis Investigative Site, Linz, A-4010, Austria|Novartis Investigative Site, Wien, A-1090, Austria|Novartis Investigative Site, Jette, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Hasselt, 3500, Belgium|Novartis Investigative Site, Brasilia, DF, 70710-904, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20.211-030, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20551-030, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 22640-102, Brazil|Novartis Investigative Site, Barretos, SP, 14784 400, Brazil|Novartis Investigative Site, Campinas, SP, 13083-970, Brazil|Novartis Investigative Site, Sao Paulo, SP, 05403 000, Brazil|Novartis Investigative Site, São Paulo, SP, 01224-000, Brazil|Novartis Investigative Site, Halifax, Nova Scotia, B3H 1V7, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2H1, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Beijing, Beijing, 100730, China|Novartis Investigative Site, Nanning, Guangxi, 530021, China|Novartis Investigative Site, Nanjing, Jiangsu, 210029, China|Novartis Investigative Site, Suzhou, Jiangsu, 215006, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Tianjin, Tianjin, 300020, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China|Novartis Investigative Site, Beijing, 100020, China|Novartis Investigative Site, Beijing, 100044, China|Novartis Investigative Site, Shanghai, 200003, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Brno Bohunice, Czech Republic, 625 00, Czechia|Novartis Investigative Site, Prague 2, Czech Republic, 128 08, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Odense, DK 5000, Denmark|Novartis Investigative Site, Vejle, DK-7100, Denmark|Novartis Investigative Site, Ålborg, DK-9100, Denmark|Novartis Investigative Site, Århus, DK-8000, Denmark|Novartis Investigative Site, Alexandria, 21131, Egypt|Novartis Investigative Site, Giza, 11451, Egypt|Novartis Investigative Site, HUS Helsinki, FIN-00029, Finland|Novartis Investigative Site, Turku, FIN-20521, Finland|Novartis Investigative Site, Blois Cedex, 41016, France|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Limoges cedex, 87042, France|Novartis Investigative Site, Nantes, 44035, France|Novartis Investigative Site, Paris, 75231, France|Novartis Investigative Site, Pierre Benite, 69310, France|Novartis Investigative Site, Strasbourg cedex, 67085, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Aachen, 52074, Germany|Novartis Investigative Site, Bad Saarow, 15526, Germany|Novartis Investigative Site, Bamberg, 96049, Germany|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Bremen, 28177, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duisburg, 47166, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Hamburg, 22763, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Muenchen, 81737, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Thessaloniki, GR, 570 10, Greece|Novartis Investigative Site, Athens, 115 28, Greece|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Territories, Hong Kong|Novartis Investigative Site, Jerusalem, 91120, Israel|Novartis Investigative Site, Kfar Saba, 4428164, Israel|Novartis Investigative Site, Petach Tikva, 49100, Israel|Novartis Investigative Site, Ramat Gan, 5265601, Israel|Novartis Investigative Site, San Giovanni Rotondo, FG, 71013, Italy|Novartis Investigative Site, Lecce, LE, 73100, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Pescara, PE, 65124, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Reggio Calabria, RC, 89124, Italy|Novartis Investigative Site, Roma, RM, 00144, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Pagani, SA, 84016, Italy|Novartis Investigative Site, Verona, VR, 37134, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Nagoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Nagoya, Aichi, 460-0001, Japan|Novartis Investigative Site, Matsuyama-city, Ehime, 790-8524, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Ogaki-city, Gifu, 503-8502, Japan|Novartis Investigative Site, Shibukawa, Gunma, 377-8511, Japan|Novartis Investigative Site, Kure-city, Hiroshima, 737-0023, Japan|Novartis Investigative Site, Higashiibaraki-gun, Ibaraki, 311-3193, Japan|Novartis Investigative Site, Okayama city, Okayama, 701-1192, Japan|Novartis Investigative Site, Suita city, Osaka, 565 0871, Japan|Novartis Investigative Site, Shibuya, Tokyo, 150-8935, Japan|Novartis Investigative Site, Hiroshima, 734-8551, Japan|Novartis Investigative Site, Niigata, 951-8566, Japan|Novartis Investigative Site, Osaka, 545-8586, Japan|Novartis Investigative Site, Suwon si, Gyeonggi Do, 16499, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Busan, 49201, Korea, Republic of|Novartis Investigative Site, Busan, 602739, Korea, Republic of|Novartis Investigative Site, Incheon, 405 760, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, 519763, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Seoul, 06351, Korea, Republic of|Novartis Investigative Site, Taegu, 41944, Korea, Republic of|Novartis Investigative Site, Beirut, 6301, Lebanon|Novartis Investigative Site, San Luis Potosí, 78218, Mexico|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, 3584 CX, Netherlands|Novartis Investigative Site, Bergen, NO-5021, Norway|Novartis Investigative Site, Fredrikstad, NO-1603, Norway|Novartis Investigative Site, Kristiansand, NO-4605, Norway|Novartis Investigative Site, Oslo, 0407, Norway|Novartis Investigative Site, Skien, NO-3710, Norway|Novartis Investigative Site, Trondheim, 7006, Norway|Novartis Investigative Site, Warszawa, 02 776, Poland|Novartis Investigative Site, Warszawa, 02-097, Poland|Novartis Investigative Site, Saratov, 410028, Russian Federation|Novartis Investigative Site, St Petersburg, 191024, Russian Federation|Novartis Investigative Site, Singapore, 169608, Singapore|Novartis Investigative Site, Parktown, 2193, South Africa|Novartis Investigative Site, Pretoria, 0027, South Africa|Novartis Investigative Site, Cordoba, Andalucia, 14004, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Pamplona, Navarra, 31008, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Göteborg, SE-413 45, Sweden|Novartis Investigative Site, Linköping, SE-581 85, Sweden|Novartis Investigative Site, Luleå, SE-971 80, Sweden|Novartis Investigative Site, Stockholm, SE-118 83, Sweden|Novartis Investigative Site, Uppsala, SE-751 85, Sweden|Novartis Investigative Site, Kaohsiung City, 83301, Taiwan|Novartis Investigative Site, Taichung, 40447, Taiwan|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Taoyuan, 333, Taiwan|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Adana, 01330, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Aberdeen, Scotland, AB25 2ZN, United Kingdom|Novartis Investigative Site, Glasgow, Scotland, G12 0YN, United Kingdom|Novartis Investigative Site, London, EC1A 7BE, United Kingdom|Novartis Investigative Site, London, SE5 9RS, United Kingdom|Novartis Investigative Site, London, W12 0HS, United Kingdom|Novartis Investigative Site, London, WC1E 6HX, United Kingdom|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom|Novartis Investigative Site, Wolverhampton, WV10 0QP, United Kingdom",
